Senaparib

CAS No. 1401682-78-7

Senaparib( IMP4297 )

Catalog No. M28788 CAS No. 1401682-78-7

Senaparib is a novel highly potent and selective oral PARP1/2 inhibitor with strong antitumor activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 92 In Stock
2MG 51 In Stock
5MG 85 In Stock
10MG 147 In Stock
25MG 275 In Stock
50MG 423 In Stock
100MG 625 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Senaparib
  • Note
    Research use only, not for human use.
  • Brief Description
    Senaparib is a novel highly potent and selective oral PARP1/2 inhibitor with strong antitumor activity.
  • Description
    Senaparib is a novel highly potent and selective oral PARP1/2 inhibitor with strong antitumor activity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    IMP4297
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    PARP
  • Recptor
    neuropeptide Y (NPY) Y1 receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1401682-78-7
  • Formula Weight
    478.45
  • Molecular Formula
    C24H20F2N6O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 83.33 mg/mL (174.17 mM)
  • SMILES
    O=C(c(cc(CN(c1cccc(F)c1C(N1)=O)C1=O)cc1)c1F)N(CC1)CCN1c1ncccn1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Antal-Zimanyi I, et al. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist. Eur J Pharmacol. 2008 Aug 20;590(1-3):224-32.
molnova catalog
related products
  • RBN012759

    RBN012759, a potent and selective PARP14 inhibitor, decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants.

  • E7016

    E7016 (GPI 21016) is an orally available PARP inhibitor that inhibits DNA repair and enhances tumor cell radiosensitivity both in vitro and in vivo.

  • Venadaparib

    Venadaparib (IDX-1197) is a potent, selective and orally active PARP inhibitor with IC50s of 1.4 nM and 1.0 nM for PARP1 and PARP2, respectively.